International Myositis Society - Special Newsletter March 2025

The new Myositis issue for 2025 is online!

Read it now and click HERE

1. Idiopathic inflammatory myopathies: one year in review 2024
   F. Fattorini, E. Conticini, E. Dourado, F. Bottazzi, L. Bruno, M. Diomedi, J. Schmidt, L. Carli, L. Cavagna, S. Barsotti
2. The classification of myositis: setting the stage for a universal terminology
   M. Giannini, S. Bhai, O. Boyer, K. Cheng, M. Johari, P. Korsten, J.B. Lilleker, D. Saygin, S. Schlüter, A.J. Van Der Kooi, J. Schmidt on behalf of the International Myositis Society (iMyoS)
3. The myositis landscape in clinical trials: 2025 and beyond
   G. Zanframundo, V. Codullo, L. Cavagna
4. Environmental triggers for idiopathic inflammatory myopathies: unravelling the known and unknown
   C. Cardelli, F. Trentin, F. Fattorini, M. Diomedi, E. Laurino, S. Barsotti, M. Mosca, L. Carli
5. Different phenotypic manifestations between Brazilian and Japanese anti-MDA5 antibody-positive dermatomyositis: an international tricentric longitudinal study
   M.S. Faria, A. Yoshida, N. Mugii, P.T. Inaoka, T. Matsushita, T. Gono, M. Kuwana, S.K. Shinjo
6. The Myositis Clinical Trials Consortium: an international collaborative initiative to promote clinical trials in adult and juvenile myositis
   A. Bishnoi, I.Y.K. Tang, A. Yoshida, F.M. Pais, S.Y. Usman, S.A. Dominguez, C.G. Kavadichanda, D. Rivero-Gallegos, E. Dourado, E. Conticini, F. Bozán, G. Tulluru, J.B. Lilleker, K. Sreerama Reddy, O. Landon-Cardinal, R. Smaili, S. Keret, T. Khoo, T.-Y. Lan, V. Leclair, C.V. Oddis, J. Vencovský, M. Kuwana, P.C. Gandiga, R. Aggarwal
   Collaborator/s: O. Benveniste, D.B. De Araujo, C. Charles-Schoeman, H. Chinoy, T.J. Corte, M.M. Dimachkie, R.P. Dodiuk-Gad, P. Eichenbrenner, M. Fujimoto, I. García-De la torre, N. Govind, N.A. Goyal, Z. Griger, R.W. Hallowell, M. Hudson, V. Limaye, L. Rajasekhar, M. Lubinus, I.E. Lundberg, S. Malloy, G. Marder, L. Metni, J. Myles, M. Needham, J. Raaphorst, L.G. Rider, J. Rojas-Serrano, J. Schmidt, A. Selva-O’callaghan, S.K. Shinjo, V. Shobha, H. So, I.B. Ventura, S. Venuturupalli, R.A. Vleugels, G. Wang, Q. Wang, E.M. Wilfong, B.M. Feldman, A.M. Huber, H. Kim, S. Kim, A. Ravelli, A. Van royen-Kerkhof on behalf of the Myositis Clinical Trials Consortium investigators
7. Clinical features and prognosis of idiopathic inflammatory myopathies with coexistent multiple myositis-specific antibodies
   X. Liang, J. Wu, H. Ren, M. Li, C. Huang, J.G. Guo, D. Li, J. Li, J. Zhu
8. Pleural effusion as a predictor of rapidly progressive interstitial lung disease and mortality in idiopathic inflammatory myopathies
   X. Liang, H. Ren, F. Xiao, S. Zheng, R. Wang, C. Huang, J. Guo, J. Li, J. Zhu
9. Self-reported physical activity and fatigue and its associations to anxiety and depression in adult patients with idiopathic inflammatory myopathies:a MIHRA psychological impact and MIHRA exercise and rehabilitation scientific working groups collaboration
   K.M. Andreasson, F. Espinosa-Ortega, H. Sandlund, H. Alexanderson
10. CD44 is associated with muscle inflammation in polymyositis and skin damage in idiopathic inflammatory myopathy
    Y. Zhou, Y. Zhao, G. Yin, L. Kang, X. Zhu, Q. Xie
11. Triple-combination therapy did not improve prognosis in anti-MDA5 positive dermatomyositis: a multicentre longitudinal cohort study
    H. You, C. Lv, L. Xu, L. Wang, T. Liu, F. Yuan, W. Yan, H. Wei, J. Wang, D. Meng, W. Tan
12. Risk prediction modelling in idiopathic inflammatory myositis-associated interstitial lung disease based on seven factors including serum KL-6 and lung ultrasound B-lines
    W. Zhang, G. Huang, S. Zheng, J. Lin, S. Hu, J. Zhuang, Z. Zhou, G. Du, K. Zheng, S. Chen, Q. Zhang, A. Mikish, A.-M. Hoffmann-Vold, M. Kuwana, M. Matucci-Cerinic, D.E. Furst, Y. Wang
13. Human epididymitis protein 4 as a biomarker of interstitial lung disease in patients with idiopathic inflammatory myopathies
    E. Zanatta, B. Moccaldi, A. Martini, L. Ienna, R. Depascale, M. Binda, M. Gatto, M. Zen, M. Tonello, A. Ghirardello, C. Giraudo, E. Balestro, M. Plebani, D. Basso, A. Doria, L. Iaccarino
14. The clinical characteristics of pharyngeal and laryngeal lesions in anti-MDA5-positive dermatomyositis patients
    W. Huang, F. Ren, D. Deng, L. Luo, J. Zhou, D. Huang, M. Tian, D. Chen, K. Qian, Y. Jiang, L. Tang
15. Utilising bioinformatics and systems biology methods to uncover the impact of dermatomyositis on interstitial lung disease
    R. Ding, D. Liang, S. Huang, X. Huang, B. Wei, S. Wan, H. Zhang, Z. Wan
16. Infections as a predominant cause of death in adult patients with idiopathic inflammatory myopathies
    A.H. Opinc-Rosiak, E.M. Kulesza, A.J. Mikosińska, O.E. Brzezińska, J.S. Makowska
17. Determining patient and carer priorities in inclusion body myositis: a patient-led research study
    K.L. Austin, B. Hawkins, K.A. Beer, A.B. Doverty, M. Needham
18. Challenges in international investigator-led rare disease clinical trials and the case for optimism in inclusion body myositis
    M. Needham, U.A. Badrising, K. Beer, A.J. Heim, A. Doverty, A. Panicker, O. Benveniste, M.M. Dimachkie
19. Optimism in inclusion body myositis: a double-blind randomised controlled phase III trial investigating the effect of sirolimus on disease progression in patients with IBM as measured by the IBM Functional Rating Scale
    U.A. Badrising, R. Henderson, S. Reddel, A. Corbett, C. Liang, K. Reardon, R. Ghaoui, M. Bulsara, S. Brady, A. Brusch, D. Chan, J.D. Coudert, T. Fairchild, G. Jain, M.C. Kiernan, D. Leonard, T. Lloyd, J. Schmidt, M.P. Mcdermott, L. Sanders, C. Lowe, A.J. Van Der Kooi, C. Weihl, P. Mohassel, M. Simpson, A. Carroll, I. Cooper, K. Beer, K. Hiscock, S. Walters, A. Panicker, A. Doverty, A. Heim, M. Van heur-Neuman, O. Benveniste, M.M. Dimachkie, M. Needham
20. TRIM63 and Atrogin-1 are key drivers of systemic and muscle inflammation in patients with idiopathic inflammatory myopathies
    A. Absalón-Aguilar, J.J. Torres-Ruiz, N.R. Mejía-Domínguez, A. Pérez-Fragoso, F. Cassiano-Quezada, M. Tapia-Rodríguez, C. Núñez-Alvarez, J. Ríos-Valencia, B. Marquina-Castillo, G. Juarez-Vega, D. Gomez-Martin
21. Quantitative muscle magnetic resonance imaging as a biomarker for inclusion body myositis in clinical trials: exploring the in vivo effects of arimoclomol
    S. Salam, J.M. Morrow, M.P. Mcdermott, N. Zafeiropoulos, J.S. Thornton, S. Shah, S. Wastling, T.Y. Yousry, R.J. Barohn, M.G. Hanna, M.M. Dimachkie, P.M. Machado
22. Disease models of myositis: overview of cell culture and rodent systems
    M. Hauke, M. Kamiya, C.C. Weihl, J. Schmidt
23. Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis
    J.J. Paik, J. Vencovský, C. Charles-Schoeman, G.C. Wright, R.A. Vleugels, A.S. Goriounova, P.N. Mudd, Jr, R. Aggarwal
24. An update on myositis autoantibodies and insights into pathogenesis
    G. Wang, N.J. Mchugh
25. Imaging evaluation of the upper limbs in inclusion body myositis: an unmet need
    S. Salam, J.M. Morrow, S. Shah, M.G. Hanna, M.M. Dimachkie, P.M. Machado
26. Longitudinal assessment of disease activity and muscle strength in juvenile dermatomyositis: a multicentre registry study
    D. Hortelan Antonio, B.O. Carneiro, T.A. Fernandes, A.M. Elias, A.J. Pantoja De Moraes, A.P. Vecchi, A. Cavalcanti, C.N. Rabelo Jr, C.M. Magalhaes, F.R. Sztajnbok, L.M. Carvalho, L. Paim Marques, M.T. Terreri, M.M. Fraga, S.K. De Oliveira, S.B. Sacchetti, S. Appenzeller, T. Robazzi, V.P. Ferriani, C.A. Len, C.A. Silva, C. Saad-Magalhaes
27. Cancer-associated myositis before and after the COVID-19 pandemic onset: a comment
    H. Daungsupawong, V. Wiwanitkit
28. Interleukin 16: a potential protective cytokine in idiopathic inflammatory myopathy
    Y. Zhou, L. Kang, T. Liu, G. Yin, Q. Xie
29. Successful management of pulmonary hypertension with baricitinib in a dermatomyositis patient
    C. Rizzo, F. Camarda, L. La Barbera, G. Guggino
30. Unravelling the link: anti-TIF1γ dermatomyositis associated with plexiform neurofibroma
    J.A. Peñafiel-Sam, I. Aldecoa, J. Milisenda, J.A. Gómez-Puerta
31. Children with immune-mediated necrotising myopathy: a case series
    Y. Yao, X.-L. He, F. Wang, G.-Q. Zhu, R.-X. Hu, G.-M. Li

Follow iMyoS on Instagram